An investigational device could help interventional cardiologists avoid the limitations of drug-eluting stents, according to a new analysis published in JACC.
It was another strong quarter for Edwards Lifesciences as the company's TAVR platform continues to gain momentum. The FDA's approval of multiple Edwards valves for the treatment of asymptomatic severe AS represents a potential game-changer for the entire industry.
Jane E Wilcox, MD, chief of heart failure treatment and recovery at Northwestern University Feinberg School of Medicine, and Neil G. Bluhm. Image courtesy of Northwestern.
Neil G. Bluhm, a billionaire philanthropist with deep ties to Chicago, has donated an additional $50 million to a high-volume facility that already bears his name.
The BioCardia delivery catheter was designed to be used by interventional cardiologists, electrophysiologists or cardiac surgeons. It includes a tiny needle that directly engages with the patient’s cardiac tissue.
The FDA has announced seven Class I recalls related to this issue. Customers are urged to destroy the devices immediately instead of returning them to the manufacturer.
